
Viraferonpeg 50mcg Injection
Marketer
MSD Pharmaceuticals Pvt Ltd
Salt Composition
Pegylated Interferon Alpha 2B (50mcg)
Overview Viraferonpeg 50mcg Injection
Peginterferon alfa-2a 50 mcg injection treats chronic hepatitis C (HCV). Administered intravenously by a healthcare provider, its duration depends on individual response and medical advice. Strict adherence to the prescribed dosage is crucial; incorrect use can lead to severe adverse reactions. While benefits may take weeks or months to appear, discontinuation should only occur under physician guidance. Common side effects include headache, dizziness, sleep disturbances, nausea, and vomiting. This medication can decrease blood cell counts, increasing infection risk; report fever, chills, rash, breathing difficulties, unusual bleeding/bruising, or dark urine immediately. Regular blood tests monitor blood cell levels, thyroid, liver, kidney function, and electrolytes. Prior to treatment, disclose any liver, kidney, or mental health conditions. Report mood changes, depression, vision problems, or suicidal ideation to your doctor. Inform your healthcare team of all other medications, as interactions are possible. This medication is contraindicated during pregnancy and breastfeeding; effective contraception is essential for both partners throughout treatment.
Uses of Viraferonpeg 50mcg Injection
Persistent infection with the hepatitis C virus (HCV)
Major Benefits of Viraferonpeg 50mcg Injection:
This medication will be administered by your healthcare provider; self-medication is strictly prohibited.
Common Side effects of Viraferonpeg 50mcg Injection:
- Abdominal pain
- Agitation
- Anxiety
- Blurred vision
- Cough
- Decreased appetite
- Decreased white blood cell count
- Depression
- Dizziness
- Dryness in mouth
- Fatigue
- Headache
- Impaired concentration
- Indigestion
- Insomnia (difficulty in sleeping)
- Nausea
- Nervousness
- Sore throat
- Stomatitis (Inflammation of the mouth)
- Viral infection
- Vomiting
How to use Viraferonpeg 50mcg Injection:
This medication will be administered by your healthcare provider. Self-medication is strictly prohibited.
How Viraferonpeg 50mcg Injection works:
Peginterferon alfa-2b (50 mcg injection) influences the body's immune response.
SAFETY ADVICE
AlcoholCAUTION
Use of Viraferonpeg 50mcg Injection with alcohol requires careful consideration. Physician consultation is recommended.
PregnancyCONSULT YOUR DOCTOR
Peginterferon alfa-2a 50mcg injection may pose risks during pregnancy. While human data is scarce, animal research indicates potential harm to a developing fetus. A physician will assess the advantages against possible dangers prior to prescribing. Seek medical advice.
Breast feedingSAFE IF PRESCRIBED
Breastfeeding mothers can likely use Viraferonpeg 50mcg Injection without significant risk to their infants. Available human data indicates minimal danger to the baby.
DrivingUNSAFE
The administration of Viraferonpeg 50mcg Injection may induce adverse reactions impacting driving capabilities. Dizziness, cognitive impairment, drowsiness, and tiredness are potential side effects that necessitate caution against operating vehicles.
KidneyUNSAFE
Individuals with kidney disease should likely avoid Viraferonpeg 50mcg Injection due to potential safety concerns. Medical advice is recommended. Patients with impaired renal function require careful monitoring when considering this medication.
LiverCONSULT YOUR DOCTOR
Insufficient data exists regarding Viraferonpeg 50mcg Injection's use in individuals with hepatic impairment. Physician consultation is advised.
What if you forget to take Viraferonpeg 50mcg Injection :
Should you forget a Viraferonpeg 50mcg Injection dose, administer it at your earliest convenience. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.
Facts to Know About Viraferonpeg 50mcg Injection
| Label | Value |
|---|---|
| Chemical Type | Interferon proteins |
| Developing Habits | No. |
| Treatment Category | Cancer Therapeutics |
| Active Class | Interferon signaling |
